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Background: An unknown location hampers removal of pancreatic tumours. We studied the effects of enzyme
inhibitors on the uptake of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]FDOPA) in the pancreas, aiming at
improved imaging of pancreatic adenocarcinoma.
Methods: Mice bearing orthotopic BxPC3 pancreatic adenocarcinoma were injected with 2-deoxy-2-[18F]fluoro-
D-glucose ([18F]FDG) and scanned with positron emission tomography/computed tomography (PET/CT). For [18F]
FDOPA studies, tumour-bearing mice and sham-operated controls were pretreated with enzyme inhibitors of
aromatic amino acid decarboxylase (AADC), catechol-O-methyl transferase (COMT), monoamine oxidase A (MAO-A)
or a combination of COMT and MAO-A. Mice were injected with [18F]FDOPA and scanned with PET/CT. The absolute
[18F]FDOPA uptake was determined from selected tissues using a gamma counter. The intratumoural biodistribution
of [18F]FDOPA was recorded by autoradiography. The main [18F]FDOPA metabolites present in the pancreata were
determined with radio-high-performance liquid chromatography.
Results: [18F]FDG uptake was high in pancreatic tumours, while [18F]FDOPA uptake was highest in the healthy
pancreas and significantly lower in tumours. [18F]FDOPA uptake in the pancreas was lowest with vehicle
pretreatment and highest with pretreatment with the inhibitor of AADC. When mice received COMT +MAO-A
inhibitors, the uptake was high in the healthy pancreas but low in the tumour-bearing pancreas.
Conclusions: Combined use of [18F]FDG and [18F]FDOPA is suitable for imaging pancreatic tumours. Unequal
pancreatic uptake after the employed enzyme inhibitors is due to the blockade of metabolism and therefore
increased availability of [18F]FDOPA metabolites, in which uptake differs from that of [18F]FDOPA. Pretreatment with
COMT +MAO-A inhibitors improved the differentiation of pancreas from the surrounding tissue and healthy
pancreas from tumour. Similar advantage was not achieved using AADC enzyme inhibitor, carbidopa.
Keywords: Pancreas, Adenocarcinoma, [18F]FDOPA, AADC, COMTBackground
Due to late diagnosis and lack of effective treatment,
pancreatic adenocarcinoma has the worst prognosis of
all of the gastrointestinal cancers [1]. Surgery is a pos-
sible curative approach if the cancer is detected early,
but the exact location of the tumour is often difficult to* Correspondence: jomitu@utu.fi
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detect only indirect signs of invasive tumour growth
such as pancreatic mass or ductal abnormalities. There-
fore, there is a need for better functional imaging tools
for the detection and localisation of pancreatic cancer.
The most frequently used positron emission tomography
(PET) tracer for tumour imaging is the glucose analogue,
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). [18F]FDG is
taken up into cells by glucose transporters, where it subse-
quently undergoes phosphorylation by hexokinase-1 intos an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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by a variety of tumour cells and reflects increased glucose
metabolism [2,3]. For pancreatic cancer, [18F]FDG has been
useful in the evaluation of indeterminate pancreatic masses,
staging of pancreatic carcinoma, detection of metastatic
disease and differentiation of viable tumours from post-
therapeutic processes like necrosis or scar tissue [4,5].
However, the diagnostic value of [18F]FDG in pancreatic
cancer is limited since inflammatory processes such as pan-
creatitis and abscesses take up [18F]FDG as well. Chronic
pancreatitis is recognised as the most common reason for
false-positive [18F]FDG-PET tumour findings in the pan-
creas [2,6].
Investigation of the functional activity of the dopamin-
ergic system is increasingly used in the evaluation of
tumours of islet cell origin [7-12]. 6-[18F]Fluoro-L-3,4-
dihydroxyphenylalanine ([18F]FDOPA), a fluorinated ana-
logue of L-DOPA, an intermediate product in dopamine
synthesis, is the most commonly used PET tracer in studies
of hyperinsulinaemia and neuroendocrine tumours [7,8]. At
present, the imaging of the pancreas using [18F]FDOPA is
focused on the neuroendocrine nature of pancreatic cells
[13]; however, the exocrine pancreas also contains dopa-
mine [14]. According to previous immunohistochemical
studies, exocrine cells can take up amine precursors such
as L-DOPA, transport them across the cell membrane, con-
vert them into dopamine by aromatic L-amino-acid decarb-
oxylase (AADC) and store them in vesicles [15-17].
In the periphery, [18F]FDOPA is extensively metabolised to
6-[18F]fluoro-L-3-methoxy-4-hydroxyphenylalanine ([18F]3-
OMFD) by catechol-O-methyltransferase (COMT) and by
AADC to 6-[18F]fluoro-L-3,4-dihydroxyphenylethylamine
(fluorodopamine, [18F]FDA), which is rapidly sulphated by
phenolsulfotransferase to fluorodopamine sulphate [18].
[18F]FDA is also transformed by monoamine oxidase
(MAO). The two isoforms of MAO, MAO-A and MAO-B,
deaminate dopamine to produce 6-[18F]fluoro-L-3,4-
dihydroxyphenylacetic acid ([18F]FDOPAC) before it is
converted into 6-[18F]fluorohomovanillic acid ([18F]FHVA)
by COMT [18,19]. [18F]FDA is also converted into 6-[18F]
fluoro-L-3-methoxytyramine by COMT before being
oxidised to [18F]FHVA by MAO (Figure 1) [20]. Carbidopa
is a potent inhibitor of AADC. Based on the metabolism
of FDOPA, carbidopa and COMT inhibitor are routinely
used in a clinic prior to [18F]FDOPA injection into
Parkinson's disease patients in order to minimise periph-
eral metabolism and to increase [18F]FDOPA concentra-
tions in the brain [21]. Carbidopa also improves imaging
of neuroendocrine tumours of the pancreas [22,23]. How-
ever, recent studies have shown that the use of enzyme in-
hibitors for other cancers of the pancreas, such as islet cell
tumours, β cell hyperplasias and insulinomas, may hamper
pancreatic uptake of [18F]FDOPA in addition to hindering
its uptake by tumour cells [24].The aim of this study was to improve the detection of
pancreatic adenocarcinoma using PET. We used [18F]FDG
and [18F]FDOPA and investigated the effects of enzyme
inhibitors on [18F]FDOPA uptake, distribution and metab-
olism by means of PET/computed tomography (CT),
autoradiography and chromatography in an orthotopic
xenograft mouse model of pancreatic adenocarcinoma.
Methods
Cell culture
Human ductal pancreatic adenocarcinoma cells (BxPC3
cells) were cultured in RPMI-1640 medium supplemented
with 10% heat-inactivated foetal calf serum and 2 mM of L-
glutamine (all from Sigma-Aldrich Chemicals, Steinheim,
Germany). The cells were maintained at 37°C in a humid
atmosphere with 5% CO2. For orthotopic inoculation, the
cells were trypsinised and suspended in Matrigel (BD Bio-
sciences, San Jose, CA, USA) at a concentration of 106 cells/
mL and stored on ice. The viability of the cells was con-
firmed by trypan blue staining before and after inoculation.
Orthotopic tumours
Five-week-old male immunodeficient nude mice (Athymic
nude/nu Foxn1 mice, Harlan, The Netherlands) were used
in this study. Animals were treated with analgesics
(TemgesicW 0.1 mg/kg, mouse body weight 23.2 ± 1.9 g)
and anaesthetised by isoflurane inhalation (3%, 200 mL/
min). After laparotomy, 30 μL of cell suspension (3 × 104
cells) was inoculated into the pancreatic body of the mice
(n = 26). Mice were weighed twice per week, and their
welfare was evaluated daily. Sham-operated nude mice
(n = 22), which were inoculated only with Matrigel, were
used as controls. Animals were sacrificed 35 or 42 days
after cancer cell inoculation. All animal studies were ap-
proved by the Finnish Animal Ethics Committee. The in-
stitutional policy on animal experimentation fully meets
the requirements defined in the National Institutes of
Health’s Guide for the Care and Use of Laboratory Animals
(NIH Publication no. 85–23, revised 1985).
Preparation of radiopharmaceuticals
[18F]FDG was synthesised from mannosyl triflate using a
nucleophilic method [26]. [18F]FDOPA was synthesised by
electrophilic fluorination from the stannylated precur-
sor 4,5-di-(1,1-dimethylethoxycarbonyl)oxy-N-formyl-
2-trimethylstannyl-L-phenylalanine ethyl ester using high
specific-radioactivity [18F]F2 as the labelling reagent
[27,28]. The specific radioactivity of [18F]FDOPA was
5.8 GBq/μmol. Radiochemical purity exceeded 98% in
every production batch [29].
Pretreatments for [18F]FDOPA
In order to minimise the peripheral metabolism of [18F]




























Figure 1 Main metabolic pathways of [18F]FDOPA (modified from [25]).
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Table 1 Ex vivo distribution of [18F]FDOPA in sham-operated and tumour-bearing mice (% ID/g)
Organ Pretreatment
Vehicle Carbidopa Ro-41-0960 Clorgyline Ro-41-0960 + clorgyline
Nonea AADCa COMTa MAO-Aa COMT +MAO-Aa
Sham Tumour Sham Tumour Sham Tumour Sham Tumour Sham Tumour
n = 6 n = 5 n = 6 n = 6 n = 2 n = 5 n = 2 n = 5 n = 6 n = 5
Pancreasb 7.3 ± 1.9 4.4 ± 2.6 24.9 ± 4.4 18.9 ± 11.9 6.8 ± 2.2 8,9 ± 2,7 7.1 ± 2.3 9.0 ± 2.3 20.4 ± 5.6 5.9 ± 4.7
Muscle 0.8 ± 0.2 1.1 ± 0.5 2.0 ± 0.5 2.2 ± 1.3 1.2 ± 0.1 1.6 ± 0.5 1.0 ± 0.0 0.9 ± 0.1 0.9 ± 0.2 1.0 ± 0.3
Liver 7.4 ± 0.6 9.7 ± 1.5 4.2 ± 0.7 4.6 ± 0.9 7.5 ± 0.5 8.2 ± 2.7 8.8 ± 0.6 7.6 ± 1.5 7.7 ± 0.8 7.6 ± 1.4
Blood 1.3 ± 0.3 1.5 ± 0.3 3.1 ± 0.5 3.3 ± 0.8 1.8 ± 0.2 2.7 ± 0.5 1.4 ± 0.0 1.3 ± 0.1 2.1 ± 0.4 2.5 ± 1.3
Heart 1.6 ± 0.4 1.9 ± 0.3 4.2 ± 0.9 4.3 ± 1.1 2.3 ± 0.3 3.5 ± 0.9 1.7 ± 0.1 1.6 ± 0.2 3.4 ± 0.2 3.6 ± 0.9
Kidneys 6.7 ± 1.6 7.8 ± 1.4 22.8 ± 3.9 19.2 ± 6.4 9.0 ± 3.1 22.0 ± 17.5 8.8 ± 4.8 6.3 ± 0.4 28.2 ± 10.7 25.9 ± 5.7
Spleen 1.6 ± 0.4 1.7 ± 0.3 4.4 ± 0.9 4.9 ± 1.5 2.8 ± 0.3 2.9 ± 0.8 1.8 ± 0.0 1.7 ± 0.3 2.9 ± 0.6 2.8 ± 0.9
Small intestine 6.2 ± 1.2 5.8 ± 1.0 4.0 ± 0.9 4.3 ± 0.8 7.0 ± 0.3 5.1 ± 0.8 10.1 ± 1.2 10.0 ± 1.9 11.1 ± 2.2 11.6 ± 1.3
Large intestine 1.2 ± 0.4 1.3 ± 0.4 1.8 ± 0.2 2.3 ± 0.5 1.5 ± 0.1 1.7 ± 0.2 2.1 ± 0.4 1.9 ± 0.3 2.9 ± 0.4 3.6 ± 1.6
Values are shown as mean ± standard deviation. aTarget enzyme; bpancreata of BxPC3 tumour-bearing animals were measured with tumours.
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and tumour-bearing animals were divided into groups
according to weight. Inhibitors and study groups are de-
scribed in Table 1. Mice were treated with carbidopa
(0.5 mg 0.25% carbomethyl cellulose sodium salt, Sigma-
Aldrich Chemicals; n = 6 + 6, sham-operated and BxPC3),
Ro-41-0960 (0.9 mg/150 μL in ethanol; n = 2 + 5),
clorgyline (0.3 mg 0.25% carbomethyl cellulose sodium
salt; n = 2 + 5) or a combination of Ro-41-0960 and
clorgyline (n = 6 + 5). All enzyme inhibitors were pur-
chased from Sigma-Aldrich Chemicals. Animals treated
with 0.9% NaCl were used as controls (n = 6 + 5). Mice
were either sacrificed for ex vivo analysis 10 min after in-
jection of [18F]FDOPA or imaged using small animal PET/
CT (Inveon Multimodality, Siemens Medical Solutions,
TN, USA).
Small-animal PET/CT and image analysis
Six weeks after orthotopic inoculation of the BxPC3 cells,
the uptake of [18F]FDG into pancreatic tumours (n = 14)
was evaluated using small animal PET/CT. [18F]FDG
(dose 9.0 ± 2.3 MBq) was injected into the tail veins of the
animals under isoflurane anaesthesia. CT was used for at-
tenuation correction of the PET data and anatomical ref-
erence following a 20-min static scan, which was acquired
in list mode at 60 min after injection. The next day, se-
lected mice (n = 4) were subjected to CT and a 20-min dy-
namic PET scan using [18F]FDOPA tracer. The injected
dose was 6.8 ± 0.1 MBq, and the injected mass was 16 ±
10 ng/g, as calculated from the known specific radioactiv-
ity at the time of injection. Images were reconstructed
using a 2D filtered backprojection with a 0.5-mm ramp fil-
ter. Data were collected for 20 min after injection of [18F]
FDOPA, and the corresponding time-activity curves were
calculated. Images were analysed using the InveonResearch Workplace software (v. 3.0). Volumes of interest
were drawn manually on the pancreas, tumours and the
left cardiac ventricle (blood). The [18F]FDOPA uptake in
tumours was expressed as time-activity curves of the pan-
creas and tumours normalised to blood radioactivity.
Uptake and intratumoural distribution of [18F]FDOPA
The whole pancreata were exposed. Tumours were not
dissected from the pancreata. Tumour volumes were cal-
culated according to the formula π/6(d1 × d2 × d3), where
d1 to d3 are perpendicular tumour diameters (mm) [30].
The absolute 18F radioactivity uptake was determined
from blood and selected abdominal tissues (Table 1) using
a gamma counter (3 in × 3 in NaI (Tl) crystal, Bicron 3
MW3/3P; Bicron Inc., Newbury, OH, USA) at 10 min
after the injection of [18F]DOPA. Tissues were weighed,
counted for radioactivity and corrected for background
radioactivity and radioactivity decay. The quantity of
radioactivity was expressed as the percentage of injected
dose per gram of tissue (% ID/g). In order to determine
the intratumoural biodistribution pattern of 18F radioactiv-
ity, tumours were rapidly frozen in dry ice/isopentane and
cut with a cryomicrotome into 20-μm sections. Tissue sec-
tions were exposed to an imaging plate (Fuji BAS TR2025,
Fuji Photo Film Co., Tokyo, Japan) for 4 ± 0.5 h. The
spatial distribution of radioactivity was recorded with a
phosphoimaging device (Fuji BAS 5000, with a resolution
of 25 μm). Images were analysed for count density
(photostimulated luminescence per unit area) with the Aida
image analysis software (v. 4.22, Raytest Isotopenmessgeräte
GmbH, Straubenhardt, Germany). The same tissue sec-
tions were stained with haematoxyline/eosin for histo-
logical analysis. Whole-tumour images were produced
using a Zeiss AxioVert 200 M microscope with AxioCam
MRc camera and the MosaiX option of AxioVision
Figure 2 Ratios to non-target tissues (pancreas-to-muscle and
pancreas-to-liver) from ex vivo radioactivity measurements
(% ID/g). These were measured after [18F]FDOPA injection. Significant
differences were detected between sham-operated and BxPC3
tumour-bearing pancreata (pretreatment adjusted p < 0.001 in
pancreas-to-muscle and pretreatment adjusted p < 0.05 in pancreas-to
-liver ratios), but pretreatment had no effect on these differences
(pretreatment × group interaction effect, p = 0.245 in pancreas-to
-muscle and p = 0.612 in pancreas-to-liver ratios). Carbidopa
pretreatment increased uptake in the pancreata of both sham-
operated and tumour-bearing mice compared with vehicle-treated
mice (group adjusted p < 0.05 in pancreas-to-muscle and group
adjusted p < 0.001 in pancreas-to-liver ratios). The numbers of mice
exposed to vehicle, carbidopa and COMT+MAO-A inhibitors were 6, 5
and 4 for sham-operated animals, respectively, and 5, 7 and 4 for
tumour-bearing animals, respectively. Values are shown as mean and
standard error.
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histological images and autoradiography were overlaid
using Adobe PhotoShop CS2 (San Jose, CA, USA), and
the outlines of the tumours were drawn on autoradiog-
raphy images according to the histological image.
High-performance liquid chromatography
Samples of pancreata were taken near the tumour,
homogenised into the high-performance liquid chromatog-
raphy (HPLC) mobile phase/methanol and centrifuged,
and the supernatant was used for metabolite analysis of
[18F]FDOPA. The HPLC method consisted of a μBondapak
C18 column (Waters Corporation, Milford, MA, USA)
which was eluted with a solution of 50 mM sodium acet-
ate, 20 mM citric acid, 1.0 mM sodium 1-octanesulfonate,
1.0 mM di-n-butylamine and 1.35 mM sodium EDTA in
water/methanol (90:10 v/v). Authentic standards of [18F]3-
OMFD, [18F]FDA, [18F]FMT, [18F]FDOPAC and [18F]
FHVA [31,32] were used to identify retention times (Rt) in
a similar chromatographic system.
Statistical analysis
The mean weight of the sham-operated pancreas and pan-
creas with a tumour was compared with a two-sample
t test. Radioactivity (ratios to non-target tissues and auto-
radiography) measurements were analysed using a two-
way analysis of variance. Models included the main effects
of pretreatment (vehicle, carbidopa and COMT+MAO-A)
and group (sham-operated and tumour-bearing animals).
In further pairwise comparisons between pretreatments,
the Tukey adjustment method was used. Interaction be-
tween pretreatment and group was also tested. Due to
positively skewed distributions, log-transformed values
were used in statistical analyses. SAS System for Windows
was used in statistical computations (v. 9.2, SAS Institute
Inc., Cary, NC, USA); p values less than 0.05 were consid-
ered as statistically significant.
Results and discussion
Tumour characterisation and ex vivo biodistribution of
[18F]FDOPA
No differences were detected between the weights of
sham-operated and tumour-bearing mice (data not
shown). No signs of cachexia were detected, which indi-
cates that the tumours were not very large (data not
shown). The tumour occurrence was 100%, and the
mean tumour volume was 50 ± 40 mm3 at 35 days after
tumour cell inoculation and 760 ± 1,300 mm3 at 42 days
after tumour cell inoculation. The mean weight of the
sham-operated pancreas was 0.18 ± 0.03 g, while the
weight of the pancreas with a tumour at 35 and 42 days
after inoculation was 0.27 ± 0.08 g (p < 0.001 vs. sham-
operated) and 0.73 ± 0.97 g (p < 0.001 vs. sham-operated),
respectively. As expected, the weight of the pancreataincreased in tumour-bearing mice compared with the
sham-operated mice.
The ex vivo distribution of [18F]FDOPA-derived activ-
ity was expressed as percentage of injected dose per
gram of tissue (Table 1). The highest amount of radio-
activity was found in the pancreas (including BxPC3 tu-
mours, as applicable), liver, kidneys and small intestine
when vehicle alone was used as pretreatment (Table 1).
Interestingly, the uptake was twofold higher in sham-
operated pancreata than in tumour-bearing pancreata
(Table 1). Carbidopa pretreatment increased the uptake in
the pancreas in sham-operated and tumour-bearing ani-
mals three- and fourfold, respectively, compared with ve-
hicle pretreatment. However, no differences were detected
between carbidopa pretreated sham-operated and tumour-
bearing animals (Table 1). Combined administration of
COMT and MAO-A inhibitors doubled the uptake of 18F
radioactivity by the pancreata of sham-operated animals
compared with vehicle pretreated animals. The 18F radio-
activity uptake in the pancreas was threefold lower in
tumour-bearing animals that received COMT+MAO-A-
inhibitors in comparison with sham-operated animals with
the same pretreatment. No major between-mice differ-
ences in other studied organs were detected. Administra-
tion of the MAO-A or COMT inhibitors alone had no
effect on 18F radioactivity uptake (Table 1), and therefore,
carbidopa and COMT+MAO-A inhibitors were selected
for further study.
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pancreas-to-liver) were calculated based on measured ra-
dioactivities (% ID/g), and they are presented in Figure 2.
Our data revealed significant differences between sham-
operated and BxPC3 tumour-bearing pancreata (pretreat-
ment adjusted p < 0.0001 in pancreas-to-muscle and
p = 0.026 in pancreas-to-liver ratios). However, these dif-
ferences were not dependent on the used pretreatment
(pretreatment × group interaction effect, p = 0.245 in
pancreas-to-muscle and p = 0.612 in pancreas-to-liver ra-
tios). Carbidopa pretreatment increased the uptake in the
pancreata in both sham-operated and tumour-bearing
mice compared with vehicle treatment (group adjusted
p = 0.037 in pancreas-to-muscle and p < 0.0001 in
pancreas-to-liver ratios), but the difference between theFigure 3 Coronal, sagittal and transaxial PET/CT images of [18F]FDG (a
observed in mice bearing orthotopic pancreatic tumours (arrows); (b) and
injection of [18F]FDOPA. Dark blue represents the lowest radioactivity, and
curves for (b) and (c) images are shown in (d), where pancreas and tumousham-operated and tumour-bearing mice was not high
enough to separate the healthy pancreas from the tumour-
bearing pancreas (Figure 2). Pretreatment with COMT+
MAO-A inhibitors increased the ratio further, especially
the pancreas-to-muscle ratio, but due to the small number
of observations and the larger variance in a measured
radioactivity in the samples, the differences did not achieve
any statistical significance (p = 0.133 in pancreas-to-muscle
and p = 0.386 in pancreas-to-liver ratios, Figure 2).
[18F]FDOPA PET imaging combined with [18F]FDG reveals
xenograft tumours in mouse pancreas
Mice were imaged with [18F]FDG PET/CT 6 weeks after
tumour cell inoculation. Orthotopic pancreatic tumours
exhibited increased glucose uptake (Figure 3a). As expected,) and [18F]FDOPA (b, c) and time-activity curves (d). These are
(c) images represent the sum of data collected 2 to 20 min after
red represents the highest radioactivity. Corresponding time-activity
r signals are corrected with ratio to blood.
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bladder, brain, kidneys and brown adipose tissue (Figure 3a).
Next, the mice were imaged with [18F]FDOPA PET/CT.
The uptake of [18F]FDOPA was very low in orthotopic
BxPC3 tumours pretreated with vehicle (Figure 3b).
However, the uptake in the healthy part of the pancreas
increased after pretreatment with COMT +MAO-A in-
hibitors (Figure 3c,d). Based on 20 min of dynamic scan-
ning, the peak and plateau radioactivities in the pancreas
were reached within 5 min (Figure 3d). The time-activity
curves of the pancreata showed similar dynamics regard-
less of pretreatment (vehicle vs. COMT+MAO-A inhi-
bitors, Figure 3d) or tumour status (sham-operated vs.
tumour-bearing mice, Figure 3d).
Autoradiography identifies low [18F]FDOPA uptake in the
tumour part of the pancreas
Intratumoural distribution of 18F radioactivity was deter-
mined by digital autoradiography. Histological images of
the haematoxylin/eosin-stained slices were combined with
autoradiography, and the tumour outlines were drawn. In
intrapancreatic comparison between the healthy pancreas
and the tumour, radioactivity uptake was on average ten-
fold lower in tumour areas than in the healthy pancreas
following pretreatments with vehicle or carbidopa. This
uptake was fivefold lower in tumours of COMT+MAO-
A pretreated pancreata (Figure 4a,b,c,d). In healthy areas
of the pancreas, uptake was dependent on pretreatment.
The uptake was uniform in the pancreata of vehicle- orFigure 4 Representative digital autoradiographs of pancreata, a corre
and radioactivity measurements. (a, b, c) In sham-operated and tumour
represents the lowest radioactivity, and red represents the highest radioact
show the locations of the tumours. (d) An image of an example of the cor
(e) Radioactivity measurements were corrected for the dose of injected rad
operated and tumour-bearing animals (pretreatment × group interaction ef
operated and tumour-bearing animals in vehicle (asterisk, p < 0.05) and CO
are shown as mean and standard error.carbidopa-treated mice (Figure 4a,b), while pretreatment
with COMT+MAO-A inhibitors led to a 2.4-fold increase
in uptake in the head of the pancreas compared with up-
take in the tail of the pancreas (Figure 4c). A representa-
tive histological image indicates tumour growth in the
body of the pancreas of mouse pretreated with COMT+
MAO-A inhibitors (Figure 4d). After normalising the up-
take with the amount of the injected radioactivity for each
pancreas, pretreatment had an effect on the difference be-
tween sham-operated and tumour-bearing animals (pre-
treatment × group interaction effect p = 0.039, Figure 4e).
Lower uptake was detected in tumour-bearing pancreata
compared with sham-operated pancreata in vehicle (p=0.016)
and COMT+MAO-A inhibitor-treated (p = 0.002) ani-
mals. In carbidopa-treated mice, no significant difference
was detected between sham-operated and tumour-bearing
animals (p = 0.733). These observations were in accord-
ance with ex vivo biodistribution data (Table 1 and
Figure 2) as well as PET/CT data (Figure 3).
Pretreatment affects [18F]FDOPA metabolism in pancreas
Metabolites were analysed in pancreatic samples of sham-
operated and tumour-bearing mice using HPLC. HPLC
radiochromatograms from a radiometabolite study are
shown in Figure 5. Of the several radiolabelled metabolites
of [18F]FDOPA (Rt = 5 min), we identified [18F]3-OMFD
(Rt = 7 min), [18F]FDOPAC (Rt = 8 min), [18F]FDA (Rt = 12
min), [18F]FHVA (Rt = 13 min) and [18F]FMT (Rt = 23
min). In the pancreata of vehicle-treated mice, three mainsponding haematoxylin and eosin-stained cryosection example
-bearing pancreata 10 min after [18F]FDOPA injection, dark blue
ivity. Black arrows highlight the tail of the pancreas, and white arrows
responding haematoxylin and eosin-stained cryosection was taken.
ioactivity. Pretreatment had effect on the difference between sham-
fect, p < 0.05). Significant differences were detected between sham-
MT +MAO-A (double asterisks, p < 0.01) pretreated pancreata. Values
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[18F]FMT. Following the carbidopa pretreatment, the main
metabolite in the samples was [18F]3-OMFD, while after
MAO-A pretreatment, [18F]3-OMFD and [18F]FMT were
identified. [18F]FDA was the major metabolite identified
following pretreatment with COMT+MAO-A inhibitors.
After the COMT pretreatment alone, the main metabolite
was [18F]FDOPAC.
At present, the treatment of pancreatic adenocarcinoma
is difficult because the location of the tumour lesion is
usually unknown. In clinical practice, pancreatic cancer is
imaged using [18F]FDG, which is the most widely used ra-
diopharmaceutical for PET [33]. However, several factors
may hamper imaging of the pancreas. Uptake of [18F]
FDG in the duodenum may cause false-positive results,
and imaging of the upper abdomen in general isFigure 5 Representative profiles of radioactive metabolites in pancre
carbidopa, COMT-inhibitor, MAO-A-inhibitor or COMT +MAO-A inhibitors.influenced by respiratory and gastrointestinal tract mo-
tion [34]. Inflammatory cells are usually present in malig-
nant lesions, further contributing to [18F]FDG uptake and
leading to false-positive tumour-related findings [3]. [18F]
FDOPA is a commonly used PET tracer for investigating
the activity of the dopaminergic system in neurological
disorders. [18F]FDOPA PET has also been successfully
used to visualise neuroendocrine, carcinoid and glomus
tumours as well as pheochromocytomas and medullary
thyroid cancers [7,35-37]. The objective of this study was
to investigate the usefulness of [18F]FDOPA also in the im-
aging of pancreatic adenocarcinoma and to assess the pos-
sible benefits of clinically available, widely used enzyme
inhibitors of catecholamine neurotransmitters.
PET/CT was used to visualise whole-body anatomical
and functional information from the tumour-bearing mice.ata after [18F]FDOPA injection. Mice were treated with vehicle,
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http://www.ejnmmires.com/content/3/1/18Initially, orthotopic pancreatic cancer was imaged using
[18F]FDG. [18F]FDG revealed increased glucose metabol-
ism in the upper left abdomen of the tumour-bearing
mice, and tumour lesions were determined based on the
anatomical location (Figure 3a). Given the limitations of
[18F]FDG, the same animals were imaged the next day
using [18F]FDOPA in order to detect pancreatic tissue. As
expected, [18F]FDOPA uptake occurred in the pancreata
of these mice, but the uptake in pancreatic BxPC3 tu-
mours was modest. According to our observations, com-
bining [18F]FDG and [18F]FDOPA imaging improves the
detection of cancerous tissue from the healthy pancreas.
Pretreatment with carbidopa or MAO and COMT inhib-
itors enhances the sensitivity of [18F]FDOPA brain imaging
in Parkinson's disease patients as well as in abdominal
tumour imaging [21,38]. In the present study, outlining of
the pancreas improved, when the animals were treated with
carbidopa or COMT and MAO-A inhibitors before [18F]
FDOPA injection. All of these enzyme inhibitors prevent
the breakdown of catecholamine neurotransmitters (Figure 1).
Inhibition of AADC with carbidopa leads to the formation
of [18F]3-OMFD (Figure 5), which is easily transported to
both tumour cells and pancreatic cells [39]. However, when
COMT+MAO-A were inhibited, the main metabolite is
[18F]FDA (Figure 5), which is not taken up by BxPC3
tumour cells. Therefore, the uptake of 18F radioactivity is
different between the healthy pancreas and tumour after
pretreatment with different enzyme inhibitors.
Ex vivo distribution studies demonstrated major (two-
to fourfold) differences in 18F-uptake ratios between
sham-operated and tumour-bearing mice, which were
pretreated with vehicle or COMT and MAO-A inhibitors
prior to [18F]FDOPA injection. This observation can be
explained by a change in [18F]FDOPA metabolism com-
pared with that following carbidopa pretreatment. This
was confirmed with tumour autoradiography. Although
uptake was highest in carbidopa-treated pancreata, the
difference between sham-operated and tumour-bearing
pancreata was largest in animals pretreated with COMT+
MAO-A inhibitors.
Conclusions
Our study indicates that pretreatment of mice with
carbidopa increases [18F]FDOPA uptake in the pancreas
and therefore facilitates the localisation of the pancreas,
but it also impairs the observer's ability to separate the
healthy pancreas from the tumour because, in addition
to exocrine pancreatic cells, tumour cells are also able to
uptake [18F]3-OMFD, which is the main metabolite after
carbidopa administration. COMT+MAO-A inhibitors in-
creased the 18F radioactivity uptake in pancreatic tissue,
while the uptake in tumours is poor due to the formation
of [18F]FDA as main metabolite. Therefore, COMT+
MAO-A inhibition improved the separation of the healthypancreas from the tumour. However, the difference be-
tween the healthy pancreas and tumour was not clear in all
cases after COMT+MAO-A administration, and the bene-
fit over vehicle pretreatment remained modest. According
to our observations, [18F]FDOPA combined with [18F]FDG
imaging is a useful tool for detecting pancreatic adeno-
carcinoma, either alone or with COMT+MAO-A pre-
treatment, but not with carbidopa pretreatment. Since
deducing the exact location of the tumour lesion is essen-
tial for a successful treatment, our data may have an im-
portant clinical value.
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